Apogee Therapeutics, Inc. (APGE)
APGE · Biological Products, (No Diagnostic Substances) · Waltham, MA · filing with the SEC since 2023
Who runs Apogee Therapeutics, Inc.
Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filedChief executive, as filed
Henderson Michael Thomas
Chief Executive Officer. First filing Jul 2023, latest Sep 3, 2026, 20 filings in all.
Officers reporting now
3
of 12 people with a filing in the last fifteen months
Directors reporting now
9
15 people on the record since 2023
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Title as filed | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Henderson Michael Thomas | Chief Executive Officer | Jul 2023 | Sep 3, 2026 | 33 · $28.4M |
| Henderson Jane | Chief Financial Officer | Jul 2023 | Sep 3, 2026 | 22 · $2.1M |
| Dambkowski Carl | Chief Medical Officer | Jul 2023 | Sep 3, 2026 | 27 · $10.2M |
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Bollinger Lisa | director | May 2024 | Sep 3, 2026 | none |
| Fairmount Funds Management LLC | director | Jul 2023 | Sep 3, 2026 | none |
| Fairmount Healthcare Fund II L.P. | director | Jul 2023 | Sep 3, 2026 | none |
| Fox Jennifer A. | director | Jul 2023 | Sep 3, 2026 | none |
| Harwin Peter Evan | director | Jul 2023 | Sep 3, 2026 | 1 · $134M |
| Jones William A Jr | director | Jul 2023 | Sep 3, 2026 | none |
| Kiselak Tomas | director | Jul 2023 | Sep 3, 2026 | none |
| Mckenna Mark C. | director | Aug 2023 | Sep 3, 2026 | none |
| Shah Nimish P | director | Jul 2023 | Sep 3, 2026 | none |
Earlier names on the record3, newest filing first
A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.